Furthermore, high CLIC3 expression is associated with increased resistance to cisplatin in ovarian cancer (OC), which is mechanistically underpinned by enhanced integrin β1 redistribution and activation of the PI3K-AKT pathway, thereby contributing to chemoresistance and metastatic competence [94]. Here, AKT1 is linked to ovarian cancer.